This analysis was performed across the control, AD, AD+LBD, and LBD groups, excluding the PSP and CBD groups, to reduce the influence of tau pathology other than that associated with AD and to assess the impact of each background pathology on the Comparison Scores. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.